Request A Quote
Contact us to discuss how we can help you achieve your research goals

About Us

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world.

Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 66 NGS-related patents, as well as more than 22,850 SCI articles with a total impact factor of more than 148,250, including publications in first tiers journals such as Cell, Nature and Science.

As the largest NGS service provider, Novogene has branches in US, UK, Germany, Singapore, Netherlands, China and Japan. Novogene was founded in 2011 and has been growing rapidly over the past few years, and has genomic sequencing labs in the US (at The University of California at Davis campus), the UK (Cambridge) , Germany , China, Singapore, and Omics CORE in Japan.


Advancing Genomics, Improving Life
Read more


To be the Global Leader in Providing Genomic Services and Solutions
Read more


Professionalism, Innovation, Integrity, Partnership
Read more



Company founder, Dr. Ruiqiang Li

Dr. Ruiqiang Li has been engaged in bioinformatics and genomics research for over a decade, developing a series of next-generation sequencing data analysis methods and software. He has participated in or led many genome research projects and published more than 100 research papers on his work, which have been cited more than 55,000 times. His publications include 38 articles in Science, Nature, and their affiliated journals. From 2014 to 2023, Dr. Li was among the top-citied Chinese authors. He has also applied for 35 invention patents.


  • Novogene opens lab and omics core in Germany and Japan respectively, continuing its global localization strategy and further enhancing regional service capabilities

    Global deployment of new technology platforms to consolidate the leading position

  • Established Guangzhou Novogene Med LAB

    The self-developed Falcon II platform is deployed globally

  • Novogene (stock code: 688315) officially launched into SSE STAR Market.

    Cambridge Sequencing Center obtained ISO/IEC 17025 accreditation and launched European Clinical Services

  • Launched Falcon, our world-leading intelligent NGS delivery platform, to significantly improve the efficiency, reliability and quality of production.

    Fought against COVID-19 pandemic and supported large-scale nucleic acid testing in Beijing, Qingdao, Tianjin, Chengdu and other places to assume social responsibility.

  • Established Novogene Netherlands B.V. and Novogene Japan k.k.

  • Received CFDA Approval for NovoFocus NSCLC CDx Test.

    Obtained CLIA certification for the UC Davis Sequencing Center.

    Established the Cambridge Sequencing Center.

  • Obtained the first CAP Certification for an NGS Lab – the first in Mainland China.

    Introduced mass spectrometry platform and expanded our multiomics service capacity.

  • Opened first sequencing center in the US at the University of California, Davis. This started the glocalization process.

  • Established Novogene (HK) Company Ltd. and started to expand overseas business.

  • Established Tianjin Sequencing Center and built a large-scale sequencing platform.

    Obtained the ‘China Medical Institution’ License, the ‘China Medical Device Manufactures’ License, and ‘Laboratory Accreditation for Gene Amplification’. Grew our clinical services.

    Established Novogene Corporation Inc. & Novogene (UK) Company Ltd., forming a model for our global operations.